{
    "doc_id": "mmlu_224_Qwen_QwQ-32B",
    "metadata": {
        "model_id": "Qwen/QwQ-32B",
        "subject": "nutrition",
        "correct_answer": "Metformin"
    },
    "raw_text": {
        "question": "What is the first-line drug for patients with type 2 diabetes and obesity, as of 2020?\n",
        "response": "Okay, so I need to figure out the first-line drug for type 2 diabetes and obesity as of 2020. Let me start by recalling what I know about diabetes medications. Type 2 diabetes management usually starts with metformin, right? But the question specifies patients who also have obesity. Hmm, maybe metformin is still the first-line, but perhaps there's another drug that's recommended when obesity is a factor?\n\nWait, I remember hearing about SGLT2 inhibitors and GLP-1 receptor agonists being used in diabetes, especially because they can also help with weight loss. The guidelines might have updated recommendations. Let me think. The American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) have guidelines. In 2019, they suggested considering metformin as first-line, but if there's obesity or cardiovascular risk, maybe GLP-1 agonists are preferred?\n\nAlso, the FDA has approved some drugs for both diabetes and weight management. For example, semaglutide (like Ozempic) is a GLP-1 agonist that's used for diabetes and weight loss. Similarly, liraglutide (Saxenda) is another one. But are these considered first-line over metformin when obesity is present?\n\nI should check the 2020 guidelines. The ADA's 2020 standards mention that metformin is still the first-line, but if there are comorbidities like obesity or CVD, other drugs can be considered. Specifically, GLP-1 agonists are recommended for weight loss and cardiovascular benefits. So maybe in patients with obesity, GLP-1 agonists are first-line instead of metformin? Or is it that metformin is still first-line but GLP-1 is an alternative?\n\nAlternatively, maybe the combination of metformin with a GLP-1 agonist is recommended? Wait, no, first-line would be the initial drug before combination. Let me think again. The key point is that for patients with obesity, the drug should address both diabetes and weight. Since metformin can sometimes cause weight gain or neutral effect, whereas GLP-1 agonists lead to weight loss, perhaps GLP-1 is preferred here.\n\nAnother angle: the FDA approved semaglutide (Wegovy) for chronic weight management in 2021, but that's post-2020. However, in 2020, maybe the guidelines already leaned towards GLP-1 agonists for obese diabetic patients. The 2020 ADA/EASD consensus might have emphasized individualizing therapy, considering factors like weight. So the first-line could still be metformin, but if obesity is a key concern, then GLP-1 agonists are preferred as first-line.\n\nAlternatively, maybe the answer is metformin remains first-line, but in the presence of obesity, a GLP-1 agonist is an alternative first-line option. I need to confirm. Let me recall specific guidelines. The 2020 ADA standards state that metformin is the initial pharmacologic therapy, but when there are specific comorbidities like obesity, a GLP-1 agonist can be considered as first-line. So the answer might be that GLP-1 receptor agonists are first-line in this scenario. Alternatively, maybe SGLT2 inhibitors? Wait, SGLT2 inhibitors like empagliflozin also have cardiovascular benefits but maybe less impact on weight compared to GLP-1.\n\nWait, GLP-1 agonists are more associated with weight loss. So for obesity, GLP-1 would be better. So putting it all together, the first-line drug for type 2 diabetes with obesity as of 2020 would be a GLP-1 receptor agonist, such as liraglutide or semaglutide. But I should check if the guidelines explicitly state that. Alternatively, maybe the answer is still metformin, but with GLP-1 as an alternative. The question says \"first-line drug\", so perhaps the primary recommendation is metformin, but in the case of obesity, the first-line might shift. Hmm.\n\nAlternatively, maybe the combination of metformin plus lifestyle is first-line, but if obesity is a key issue, then GLP-1 is added or used instead. I think the key point is that in 2020, the guidelines started to recommend GLP-1 agonists as first-line options in certain situations, especially when weight loss is needed. So the answer is GLP-1 receptor agonists. Let me confirm with a quick search in my mind: yes, the 2020 ADA guidelines do mention that in patients with obesity, GLP-1 agonists can be considered as first-line. So the answer is GLP-1 agonists like liraglutide or semaglutide. Alternatively, the specific drug name? The question might expect the class, so GLP-1 receptor agonists. But maybe the most commonly cited one is semaglutide. Wait, but the question says \"first-line drug\", so perhaps the class is acceptable. Alternatively, the answer is metformin unless there's a specific reason, but with obesity, GLP-1 is an option. Hmm. I think the correct answer is that metformin is still first-line generally, but in the presence of obesity, GLP-1 agonists are recommended as first-line. Therefore, the answer would be GLP-1 receptor agonists.\n</think>\n\nAs of 2020, the **first-line pharmacologic treatment for type 2 diabetes** in general remains **metformin**, as recommended by guidelines such as those from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). However, when **obesity** is a comorbidity, guidelines emphasize **individualizing therapy** to address both hyperglycemia and weight management. \n\nIn this context, **GLP-1 receptor agonists** (e.g., liraglutide, semaglutide, or dulaglutide) are often prioritized as **first-line options** due to their dual benefits of **improving glycemic control** and **promoting weight loss**, alongside cardiovascular protective effects. These agents are particularly favored when obesity or cardiovascular risk factors are present. \n\n### Key Points:\n1. **Metformin** remains the **initial therapy** for most patients with type 2 diabetes.\n2. For patients with **obesity**, **GLP-1 receptor agonists** are recommended as **first-line alternatives** to metformin, given their efficacy in weight reduction and cardiovascular benefits.\n3. The 2020 ADA/EASD consensus supports using GLP-1 agonists in this population to address both diabetes and obesity effectively.\n\nThus, the **first-line drug for type 2 diabetes with obesity** as of 2020 is **a GLP-1 receptor agonist** (e.g., semaglutide or liraglutide)."
    },
    "nodes": [
        {
            "id": "ctx0",
            "annotation": false,
            "start": 0,
            "end": 87,
            "label": "context",
            "text": "What is the first-line drug for patients with type 2 diabetes and obesity, as of 2020?\n",
            "source": "question"
        },
        {
            "id": "resp0",
            "annotation": false,
            "start": 0,
            "end": 94,
            "label": "restatement",
            "text": "Okay, so I need to figure out the first-line drug for type 2 diabetes and obesity as of 2020. ",
            "source": "response"
        },
        {
            "id": "resp1",
            "annotation": false,
            "start": 94,
            "end": 160,
            "label": "planning",
            "text": "Let me start by recalling what I know about diabetes medications. ",
            "source": "response"
        },
        {
            "id": "resp2",
            "annotation": false,
            "start": 160,
            "end": 225,
            "label": "fact",
            "text": "Type 2 diabetes management usually starts with metformin, right? ",
            "source": "response"
        },
        {
            "id": "resp3",
            "annotation": false,
            "start": 225,
            "end": 284,
            "label": "restatement",
            "text": "But the question specifies patients who also have obesity. ",
            "source": "response"
        },
        {
            "id": "resp4",
            "annotation": false,
            "start": 284,
            "end": 409,
            "label": "reasoning",
            "text": "Hmm, maybe metformin is still the first-line, but perhaps there's another drug that's recommended when obesity is a factor?\n\n",
            "source": "response"
        },
        {
            "id": "resp5",
            "annotation": false,
            "start": 409,
            "end": 565,
            "label": "fact",
            "text": "Wait, I remember hearing about SGLT2 inhibitors and GLP-1 receptor agonists being used in diabetes, especially because they can also help with weight loss. ",
            "source": "response"
        },
        {
            "id": "resp6",
            "annotation": false,
            "start": 565,
            "end": 616,
            "label": "planning",
            "text": "The guidelines might have updated recommendations. ",
            "source": "response"
        },
        {
            "id": "resp7",
            "annotation": false,
            "start": 616,
            "end": 630,
            "label": "planning",
            "text": "Let me think. ",
            "source": "response"
        },
        {
            "id": "resp8",
            "annotation": false,
            "start": 630,
            "end": 745,
            "label": "fact",
            "text": "The American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) have guidelines. ",
            "source": "response"
        },
        {
            "id": "resp9",
            "annotation": false,
            "start": 745,
            "end": 890,
            "label": "reasoning",
            "text": "In 2019, they suggested considering metformin as first-line, but if there's obesity or cardiovascular risk, maybe GLP-1 agonists are preferred?\n\n",
            "source": "response"
        },
        {
            "id": "resp10",
            "annotation": false,
            "start": 890,
            "end": 969,
            "label": "fact",
            "text": "Also, the FDA has approved some drugs for both diabetes and weight management. ",
            "source": "response"
        },
        {
            "id": "resp11",
            "annotation": false,
            "start": 969,
            "end": 1070,
            "label": "fact",
            "text": "For example, semaglutide (like Ozempic) is a GLP-1 agonist that's used for diabetes and weight loss. ",
            "source": "response"
        },
        {
            "id": "resp12",
            "annotation": false,
            "start": 1070,
            "end": 1119,
            "label": "fact",
            "text": "Similarly, liraglutide (Saxenda) is another one. ",
            "source": "response"
        },
        {
            "id": "resp13",
            "annotation": false,
            "start": 1119,
            "end": 1196,
            "label": "planning",
            "text": "But are these considered first-line over metformin when obesity is present?\n\n",
            "source": "response"
        },
        {
            "id": "resp14",
            "annotation": false,
            "start": 1196,
            "end": 1232,
            "label": "planning",
            "text": "I should check the 2020 guidelines. ",
            "source": "response"
        },
        {
            "id": "resp15",
            "annotation": false,
            "start": 1232,
            "end": 1388,
            "label": "fact",
            "text": "The ADA's 2020 standards mention that metformin is still the first-line, but if there are comorbidities like obesity or CVD, other drugs can be considered. ",
            "source": "response"
        },
        {
            "id": "resp16",
            "annotation": false,
            "start": 1388,
            "end": 1478,
            "label": "fact",
            "text": "Specifically, GLP-1 agonists are recommended for weight loss and cardiovascular benefits. ",
            "source": "response"
        },
        {
            "id": "resp17",
            "annotation": false,
            "start": 1478,
            "end": 1565,
            "label": "reasoning",
            "text": "So maybe in patients with obesity, GLP-1 agonists are first-line instead of metformin? ",
            "source": "response"
        },
        {
            "id": "resp18",
            "annotation": false,
            "start": 1565,
            "end": 1639,
            "label": "reasoning",
            "text": "Or is it that metformin is still first-line but GLP-1 is an alternative?\n\n",
            "source": "response"
        },
        {
            "id": "resp19",
            "annotation": false,
            "start": 1639,
            "end": 1726,
            "label": "planning",
            "text": "Alternatively, maybe the combination of metformin with a GLP-1 agonist is recommended? ",
            "source": "response"
        },
        {
            "id": "resp20",
            "annotation": false,
            "start": 1726,
            "end": 1793,
            "label": "restatement",
            "text": "Wait, no, first-line would be the initial drug before combination. ",
            "source": "response"
        },
        {
            "id": "resp21",
            "annotation": false,
            "start": 1793,
            "end": 1813,
            "label": "planning",
            "text": "Let me think again. ",
            "source": "response"
        },
        {
            "id": "resp22",
            "annotation": false,
            "start": 1813,
            "end": 1912,
            "label": "fact",
            "text": "The key point is that for patients with obesity, the drug should address both diabetes and weight. ",
            "source": "response"
        },
        {
            "id": "resp23",
            "annotation": false,
            "start": 1912,
            "end": 2057,
            "label": "reasoning",
            "text": "Since metformin can sometimes cause weight gain or neutral effect, whereas GLP-1 agonists lead to weight loss, perhaps GLP-1 is preferred here.\n\n",
            "source": "response"
        },
        {
            "id": "resp24",
            "annotation": false,
            "start": 2057,
            "end": 2171,
            "label": "fact",
            "text": "Another angle: the FDA approved semaglutide (Wegovy) for chronic weight management in 2021, but that's post-2020. ",
            "source": "response"
        },
        {
            "id": "resp25",
            "annotation": false,
            "start": 2171,
            "end": 2277,
            "label": "reasoning",
            "text": "However, in 2020, maybe the guidelines already leaned towards GLP-1 agonists for obese diabetic patients. ",
            "source": "response"
        },
        {
            "id": "resp26",
            "annotation": false,
            "start": 2277,
            "end": 2385,
            "label": "fact",
            "text": "The 2020 ADA/EASD consensus might have emphasized individualizing therapy, considering factors like weight. ",
            "source": "response"
        },
        {
            "id": "resp27",
            "annotation": false,
            "start": 2385,
            "end": 2512,
            "label": "reasoning",
            "text": "So the first-line could still be metformin, but if obesity is a key concern, then GLP-1 agonists are preferred as first-line.\n\n",
            "source": "response"
        },
        {
            "id": "resp28",
            "annotation": false,
            "start": 2512,
            "end": 2662,
            "label": "reasoning",
            "text": "Alternatively, maybe the answer is metformin remains first-line, but in the presence of obesity, a GLP-1 agonist is an alternative first-line option. ",
            "source": "response"
        },
        {
            "id": "resp29",
            "annotation": false,
            "start": 2662,
            "end": 2681,
            "label": "planning",
            "text": "I need to confirm. ",
            "source": "response"
        },
        {
            "id": "resp30",
            "annotation": false,
            "start": 2681,
            "end": 2716,
            "label": "planning",
            "text": "Let me recall specific guidelines. ",
            "source": "response"
        },
        {
            "id": "resp31",
            "annotation": false,
            "start": 2716,
            "end": 2903,
            "label": "fact",
            "text": "The 2020 ADA standards state that metformin is the initial pharmacologic therapy, but when there are specific comorbidities like obesity, a GLP-1 agonist can be considered as first-line. ",
            "source": "response"
        },
        {
            "id": "resp32",
            "annotation": false,
            "start": 2903,
            "end": 2988,
            "label": "reasoning",
            "text": "So the answer might be that GLP-1 receptor agonists are first-line in this scenario. ",
            "source": "response"
        },
        {
            "id": "resp33",
            "annotation": false,
            "start": 2988,
            "end": 3027,
            "label": "planning",
            "text": "Alternatively, maybe SGLT2 inhibitors? ",
            "source": "response"
        },
        {
            "id": "resp34",
            "annotation": false,
            "start": 3027,
            "end": 3155,
            "label": "fact",
            "text": "Wait, SGLT2 inhibitors like empagliflozin also have cardiovascular benefits but maybe less impact on weight compared to GLP-1.\n\n",
            "source": "response"
        },
        {
            "id": "resp35",
            "annotation": false,
            "start": 3155,
            "end": 3214,
            "label": "fact",
            "text": "Wait, GLP-1 agonists are more associated with weight loss. ",
            "source": "response"
        },
        {
            "id": "resp36",
            "annotation": false,
            "start": 3214,
            "end": 3253,
            "label": "reasoning",
            "text": "So for obesity, GLP-1 would be better. ",
            "source": "response"
        },
        {
            "id": "resp37",
            "annotation": false,
            "start": 3253,
            "end": 3416,
            "label": "reasoning",
            "text": "So putting it all together, the first-line drug for type 2 diabetes with obesity as of 2020 would be a GLP-1 receptor agonist, such as liraglutide or semaglutide. ",
            "source": "response"
        },
        {
            "id": "resp38",
            "annotation": false,
            "start": 3416,
            "end": 3476,
            "label": "planning",
            "text": "But I should check if the guidelines explicitly state that. ",
            "source": "response"
        },
        {
            "id": "resp39",
            "annotation": false,
            "start": 3476,
            "end": 3562,
            "label": "reasoning",
            "text": "Alternatively, maybe the answer is still metformin, but with GLP-1 as an alternative. ",
            "source": "response"
        },
        {
            "id": "resp40",
            "annotation": false,
            "start": 3562,
            "end": 3713,
            "label": "reasoning",
            "text": "The question says \"first-line drug\", so perhaps the primary recommendation is metformin, but in the case of obesity, the first-line might shift. Hmm.\n\n",
            "source": "response"
        },
        {
            "id": "resp41",
            "annotation": false,
            "start": 3713,
            "end": 3861,
            "label": "reasoning",
            "text": "Alternatively, maybe the combination of metformin plus lifestyle is first-line, but if obesity is a key issue, then GLP-1 is added or used instead. ",
            "source": "response"
        },
        {
            "id": "resp42",
            "annotation": false,
            "start": 3861,
            "end": 4035,
            "label": "fact",
            "text": "I think the key point is that in 2020, the guidelines started to recommend GLP-1 agonists as first-line options in certain situations, especially when weight loss is needed. ",
            "source": "response"
        },
        {
            "id": "resp43",
            "annotation": false,
            "start": 4035,
            "end": 4077,
            "label": "reasoning",
            "text": "So the answer is GLP-1 receptor agonists. ",
            "source": "response"
        },
        {
            "id": "resp44",
            "annotation": false,
            "start": 4077,
            "end": 4243,
            "label": "fact",
            "text": "Let me confirm with a quick search in my mind: yes, the 2020 ADA guidelines do mention that in patients with obesity, GLP-1 agonists can be considered as first-line. ",
            "source": "response"
        },
        {
            "id": "resp45",
            "annotation": false,
            "start": 4243,
            "end": 4308,
            "label": "reasoning",
            "text": "So the answer is GLP-1 agonists like liraglutide or semaglutide. ",
            "source": "response"
        },
        {
            "id": "resp46",
            "annotation": false,
            "start": 4308,
            "end": 4347,
            "label": "planning",
            "text": "Alternatively, the specific drug name? ",
            "source": "response"
        },
        {
            "id": "resp47",
            "annotation": false,
            "start": 4347,
            "end": 4412,
            "label": "reasoning",
            "text": "The question might expect the class, so GLP-1 receptor agonists. ",
            "source": "response"
        },
        {
            "id": "resp48",
            "annotation": false,
            "start": 4412,
            "end": 4466,
            "label": "reasoning",
            "text": "But maybe the most commonly cited one is semaglutide. ",
            "source": "response"
        },
        {
            "id": "resp49",
            "annotation": false,
            "start": 4466,
            "end": 4549,
            "label": "reasoning",
            "text": "Wait, but the question says \"first-line drug\", so perhaps the class is acceptable. ",
            "source": "response"
        },
        {
            "id": "resp50",
            "annotation": false,
            "start": 4549,
            "end": 4660,
            "label": "reasoning",
            "text": "Alternatively, the answer is metformin unless there's a specific reason, but with obesity, GLP-1 is an option. ",
            "source": "response"
        },
        {
            "id": "resp51",
            "annotation": false,
            "start": 4660,
            "end": 4665,
            "label": "reflection",
            "text": "Hmm. ",
            "source": "response"
        },
        {
            "id": "resp52",
            "annotation": false,
            "start": 4665,
            "end": 4819,
            "label": "reasoning",
            "text": "I think the correct answer is that metformin is still first-line generally, but in the presence of obesity, GLP-1 agonists are recommended as first-line. ",
            "source": "response"
        },
        {
            "id": "resp53",
            "annotation": false,
            "start": 4819,
            "end": 4885,
            "label": "reasoning",
            "text": "Therefore, the answer would be GLP-1 receptor agonists.\n</think>\n\n",
            "source": "response"
        },
        {
            "id": "resp54",
            "annotation": false,
            "start": 4885,
            "end": 5145,
            "label": "fact",
            "text": "As of 2020, the **first-line pharmacologic treatment for type 2 diabetes** in general remains **metformin**, as recommended by guidelines such as those from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). ",
            "source": "response"
        },
        {
            "id": "resp55",
            "annotation": false,
            "start": 5145,
            "end": 5293,
            "label": "fact",
            "text": "However, when **obesity** is a comorbidity, guidelines emphasize **individualizing therapy** to address both hyperglycemia and weight management. \n\n",
            "source": "response"
        },
        {
            "id": "resp56",
            "annotation": false,
            "start": 5293,
            "end": 5572,
            "label": "fact",
            "text": "In this context, **GLP-1 receptor agonists** (e.g., liraglutide, semaglutide, or dulaglutide) are often prioritized as **first-line options** due to their dual benefits of **improving glycemic control** and **promoting weight loss**, alongside cardiovascular protective effects. ",
            "source": "response"
        },
        {
            "id": "resp57",
            "annotation": false,
            "start": 5572,
            "end": 5669,
            "label": "fact",
            "text": "These agents are particularly favored when obesity or cardiovascular risk factors are present. \n\n",
            "source": "response"
        },
        {
            "id": "resp58",
            "annotation": false,
            "start": 5669,
            "end": 5685,
            "label": "planning",
            "text": "### Key Points:\n",
            "source": "response"
        },
        {
            "id": "resp59",
            "annotation": false,
            "start": 5685,
            "end": 5774,
            "label": "fact",
            "text": "1. **Metformin** remains the **initial therapy** for most patients with type 2 diabetes.\n",
            "source": "response"
        },
        {
            "id": "resp60",
            "annotation": false,
            "start": 5774,
            "end": 5967,
            "label": "fact",
            "text": "2. For patients with **obesity**, **GLP-1 receptor agonists** are recommended as **first-line alternatives** to metformin, given their efficacy in weight reduction and cardiovascular benefits.\n",
            "source": "response"
        },
        {
            "id": "resp61",
            "annotation": false,
            "start": 5967,
            "end": 6098,
            "label": "fact",
            "text": "3. The 2020 ADA/EASD consensus supports using GLP-1 agonists in this population to address both diabetes and obesity effectively.\n\n",
            "source": "response"
        },
        {
            "id": "resp62",
            "annotation": false,
            "start": 6098,
            "end": 6239,
            "label": "conclusion",
            "text": "Thus, the **first-line drug for type 2 diabetes with obesity** as of 2020 is **a GLP-1 receptor agonist** (e.g., semaglutide or liraglutide).",
            "source": "response"
        }
    ],
    "edges": [
        {
            "id": "e0",
            "from_node_id": "ctx0",
            "to_node_id": "resp0",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e1",
            "from_node_id": "resp0",
            "to_node_id": "resp1",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e2",
            "from_node_id": "resp1",
            "to_node_id": "resp2",
            "label": "reason:plan-step"
        },
        {
            "id": "e3",
            "from_node_id": "resp0",
            "to_node_id": "resp3",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e4",
            "from_node_id": "resp2",
            "to_node_id": "resp3",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e5",
            "from_node_id": "resp2",
            "to_node_id": "resp4",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e6",
            "from_node_id": "resp3",
            "to_node_id": "resp4",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e7",
            "from_node_id": "resp4",
            "to_node_id": "resp5",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e8",
            "from_node_id": "resp4",
            "to_node_id": "resp6",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e9",
            "from_node_id": "resp5",
            "to_node_id": "resp6",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e10",
            "from_node_id": "resp6",
            "to_node_id": "resp7",
            "label": "plan:frontier-verify"
        },
        {
            "id": "e11",
            "from_node_id": "resp6",
            "to_node_id": "resp8",
            "label": "plan:plan-subplan"
        },
        {
            "id": "e12",
            "from_node_id": "resp7",
            "to_node_id": "resp8",
            "label": "plan:plan-subplan"
        },
        {
            "id": "e13",
            "from_node_id": "resp4",
            "to_node_id": "resp9",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e14",
            "from_node_id": "resp6",
            "to_node_id": "resp9",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e15",
            "from_node_id": "resp8",
            "to_node_id": "resp9",
            "label": "reason:fact-detail"
        },
        {
            "id": "e16",
            "from_node_id": "resp7",
            "to_node_id": "resp10",
            "label": "reason:plan-step"
        },
        {
            "id": "e17",
            "from_node_id": "resp9",
            "to_node_id": "resp10",
            "label": "reason:fact-detail"
        },
        {
            "id": "e18",
            "from_node_id": "resp9",
            "to_node_id": "resp11",
            "label": "reason:fact-detail"
        },
        {
            "id": "e19",
            "from_node_id": "resp10",
            "to_node_id": "resp11",
            "label": "reason:fact-detail"
        },
        {
            "id": "e20",
            "from_node_id": "resp11",
            "to_node_id": "resp12",
            "label": "reason:fact-detail"
        },
        {
            "id": "e21",
            "from_node_id": "resp6",
            "to_node_id": "resp13",
            "label": "plan:frontier-verify"
        },
        {
            "id": "e22",
            "from_node_id": "resp9",
            "to_node_id": "resp13",
            "label": "plan:frontier-verify"
        },
        {
            "id": "e23",
            "from_node_id": "resp13",
            "to_node_id": "resp14",
            "label": "plan:frontier-verify"
        },
        {
            "id": "e24",
            "from_node_id": "resp9",
            "to_node_id": "resp15",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e25",
            "from_node_id": "resp14",
            "to_node_id": "resp15",
            "label": "plan:plan-nextplan"
        },
        {
            "id": "e26",
            "from_node_id": "resp15",
            "to_node_id": "resp16",
            "label": "reason:fact-detail"
        },
        {
            "id": "e27",
            "from_node_id": "resp4",
            "to_node_id": "resp17",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e28",
            "from_node_id": "resp13",
            "to_node_id": "resp17",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e29",
            "from_node_id": "resp14",
            "to_node_id": "resp17",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e30",
            "from_node_id": "resp15",
            "to_node_id": "resp17",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e31",
            "from_node_id": "resp16",
            "to_node_id": "resp17",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e32",
            "from_node_id": "resp13",
            "to_node_id": "resp18",
            "label": "plan:frontier-verify"
        },
        {
            "id": "e33",
            "from_node_id": "resp15",
            "to_node_id": "resp18",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e34",
            "from_node_id": "resp16",
            "to_node_id": "resp18",
            "label": "reason:fact-detail"
        },
        {
            "id": "e35",
            "from_node_id": "resp17",
            "to_node_id": "resp18",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e36",
            "from_node_id": "resp17",
            "to_node_id": "resp19",
            "label": "plan:frontier-verify"
        },
        {
            "id": "e37",
            "from_node_id": "resp18",
            "to_node_id": "resp19",
            "label": "plan:plan-alternative"
        },
        {
            "id": "e38",
            "from_node_id": "resp18",
            "to_node_id": "resp20",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e39",
            "from_node_id": "resp19",
            "to_node_id": "resp20",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e40",
            "from_node_id": "resp20",
            "to_node_id": "resp21",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e41",
            "from_node_id": "resp17",
            "to_node_id": "resp22",
            "label": "reason:fact-detail"
        },
        {
            "id": "e42",
            "from_node_id": "resp18",
            "to_node_id": "resp22",
            "label": "reason:fact-detail"
        },
        {
            "id": "e43",
            "from_node_id": "resp4",
            "to_node_id": "resp23",
            "label": "evaluate:refute"
        },
        {
            "id": "e44",
            "from_node_id": "resp17",
            "to_node_id": "resp23",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e45",
            "from_node_id": "resp22",
            "to_node_id": "resp23",
            "label": "evaluate:support"
        },
        {
            "id": "e46",
            "from_node_id": "resp19",
            "to_node_id": "resp24",
            "label": "reason:plan-step"
        },
        {
            "id": "e47",
            "from_node_id": "resp23",
            "to_node_id": "resp24",
            "label": "reason:fact-detail"
        },
        {
            "id": "e48",
            "from_node_id": "resp15",
            "to_node_id": "resp25",
            "label": "evaluate:support"
        },
        {
            "id": "e49",
            "from_node_id": "resp16",
            "to_node_id": "resp25",
            "label": "evaluate:support"
        },
        {
            "id": "e50",
            "from_node_id": "resp18",
            "to_node_id": "resp25",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e51",
            "from_node_id": "resp19",
            "to_node_id": "resp25",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e52",
            "from_node_id": "resp23",
            "to_node_id": "resp25",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e53",
            "from_node_id": "resp14",
            "to_node_id": "resp26",
            "label": "reason:plan-step"
        },
        {
            "id": "e54",
            "from_node_id": "resp25",
            "to_node_id": "resp26",
            "label": "reason:fact-detail"
        },
        {
            "id": "e55",
            "from_node_id": "resp17",
            "to_node_id": "resp27",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e56",
            "from_node_id": "resp18",
            "to_node_id": "resp27",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e57",
            "from_node_id": "resp22",
            "to_node_id": "resp27",
            "label": "evaluate:support"
        },
        {
            "id": "e58",
            "from_node_id": "resp23",
            "to_node_id": "resp27",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e59",
            "from_node_id": "resp25",
            "to_node_id": "resp27",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e60",
            "from_node_id": "resp18",
            "to_node_id": "resp28",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e61",
            "from_node_id": "resp19",
            "to_node_id": "resp28",
            "label": "plan:plan-alternative"
        },
        {
            "id": "e62",
            "from_node_id": "resp27",
            "to_node_id": "resp28",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e63",
            "from_node_id": "resp28",
            "to_node_id": "resp29",
            "label": "plan:frontier-verify"
        },
        {
            "id": "e64",
            "from_node_id": "resp29",
            "to_node_id": "resp30",
            "label": "plan:plan-nextplan"
        },
        {
            "id": "e65",
            "from_node_id": "resp27",
            "to_node_id": "resp31",
            "label": "reason:fact-detail"
        },
        {
            "id": "e66",
            "from_node_id": "resp28",
            "to_node_id": "resp31",
            "label": "reason:fact-detail"
        },
        {
            "id": "e67",
            "from_node_id": "resp29",
            "to_node_id": "resp31",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e68",
            "from_node_id": "resp30",
            "to_node_id": "resp31",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e69",
            "from_node_id": "resp27",
            "to_node_id": "resp32",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e70",
            "from_node_id": "resp28",
            "to_node_id": "resp32",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e71",
            "from_node_id": "resp31",
            "to_node_id": "resp32",
            "label": "reason:fact-detail"
        },
        {
            "id": "e72",
            "from_node_id": "resp28",
            "to_node_id": "resp33",
            "label": "plan:plan-alternative"
        },
        {
            "id": "e73",
            "from_node_id": "resp32",
            "to_node_id": "resp33",
            "label": "plan:frontier-verify"
        },
        {
            "id": "e74",
            "from_node_id": "resp33",
            "to_node_id": "resp34",
            "label": "reason:plan-step"
        },
        {
            "id": "e75",
            "from_node_id": "resp23",
            "to_node_id": "resp35",
            "label": "reason:fact-detail"
        },
        {
            "id": "e76",
            "from_node_id": "resp34",
            "to_node_id": "resp35",
            "label": "reason:fact-detail"
        },
        {
            "id": "e77",
            "from_node_id": "resp22",
            "to_node_id": "resp36",
            "label": "reason:fact-detail"
        },
        {
            "id": "e78",
            "from_node_id": "resp23",
            "to_node_id": "resp36",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e79",
            "from_node_id": "resp27",
            "to_node_id": "resp36",
            "label": "reason:plan-step"
        },
        {
            "id": "e80",
            "from_node_id": "resp28",
            "to_node_id": "resp36",
            "label": "reason:plan-step"
        },
        {
            "id": "e81",
            "from_node_id": "resp35",
            "to_node_id": "resp36",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e82",
            "from_node_id": "resp23",
            "to_node_id": "resp37",
            "label": "evaluate:support"
        },
        {
            "id": "e83",
            "from_node_id": "resp31",
            "to_node_id": "resp37",
            "label": "evaluate:support"
        },
        {
            "id": "e84",
            "from_node_id": "resp32",
            "to_node_id": "resp37",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e85",
            "from_node_id": "resp36",
            "to_node_id": "resp37",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e86",
            "from_node_id": "resp29",
            "to_node_id": "resp38",
            "label": "plan:plan-nextplan"
        },
        {
            "id": "e87",
            "from_node_id": "resp30",
            "to_node_id": "resp38",
            "label": "plan:plan-nextplan"
        },
        {
            "id": "e88",
            "from_node_id": "resp37",
            "to_node_id": "resp38",
            "label": "plan:frontier-verify"
        },
        {
            "id": "e89",
            "from_node_id": "resp28",
            "to_node_id": "resp39",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e90",
            "from_node_id": "resp37",
            "to_node_id": "resp39",
            "label": "evaluate:refute"
        },
        {
            "id": "e91",
            "from_node_id": "resp18",
            "to_node_id": "resp40",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e92",
            "from_node_id": "resp27",
            "to_node_id": "resp40",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e93",
            "from_node_id": "resp28",
            "to_node_id": "resp40",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e94",
            "from_node_id": "resp32",
            "to_node_id": "resp40",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e95",
            "from_node_id": "resp37",
            "to_node_id": "resp40",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e96",
            "from_node_id": "resp19",
            "to_node_id": "resp41",
            "label": "reason:plan-step"
        },
        {
            "id": "e97",
            "from_node_id": "resp20",
            "to_node_id": "resp41",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e98",
            "from_node_id": "resp22",
            "to_node_id": "resp41",
            "label": "reason:fact-detail"
        },
        {
            "id": "e99",
            "from_node_id": "resp23",
            "to_node_id": "resp41",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e100",
            "from_node_id": "resp27",
            "to_node_id": "resp41",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e101",
            "from_node_id": "resp28",
            "to_node_id": "resp41",
            "label": "reason:plan-step"
        },
        {
            "id": "e102",
            "from_node_id": "resp37",
            "to_node_id": "resp41",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e103",
            "from_node_id": "resp39",
            "to_node_id": "resp41",
            "label": "reason:plan-step"
        },
        {
            "id": "e104",
            "from_node_id": "resp40",
            "to_node_id": "resp41",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e105",
            "from_node_id": "resp27",
            "to_node_id": "resp42",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e106",
            "from_node_id": "resp31",
            "to_node_id": "resp42",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e107",
            "from_node_id": "resp37",
            "to_node_id": "resp42",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e108",
            "from_node_id": "resp41",
            "to_node_id": "resp42",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e109",
            "from_node_id": "resp32",
            "to_node_id": "resp43",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e110",
            "from_node_id": "resp37",
            "to_node_id": "resp43",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e111",
            "from_node_id": "resp42",
            "to_node_id": "resp43",
            "label": "evaluate:support"
        },
        {
            "id": "e112",
            "from_node_id": "resp39",
            "to_node_id": "resp44",
            "label": "evaluate:refute"
        },
        {
            "id": "e113",
            "from_node_id": "resp42",
            "to_node_id": "resp44",
            "label": "evaluate:support"
        },
        {
            "id": "e114",
            "from_node_id": "resp43",
            "to_node_id": "resp44",
            "label": "evaluate:support"
        },
        {
            "id": "e115",
            "from_node_id": "resp42",
            "to_node_id": "resp45",
            "label": "evaluate:support"
        },
        {
            "id": "e116",
            "from_node_id": "resp43",
            "to_node_id": "resp45",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e117",
            "from_node_id": "resp44",
            "to_node_id": "resp45",
            "label": "evaluate:support"
        },
        {
            "id": "e118",
            "from_node_id": "resp43",
            "to_node_id": "resp46",
            "label": "plan:plan-alternative"
        },
        {
            "id": "e119",
            "from_node_id": "resp45",
            "to_node_id": "resp46",
            "label": "plan:plan-alternative"
        },
        {
            "id": "e120",
            "from_node_id": "resp43",
            "to_node_id": "resp47",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e121",
            "from_node_id": "resp44",
            "to_node_id": "resp47",
            "label": "evaluate:support"
        },
        {
            "id": "e122",
            "from_node_id": "resp45",
            "to_node_id": "resp47",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e123",
            "from_node_id": "resp35",
            "to_node_id": "resp48",
            "label": "reason:fact-detail"
        },
        {
            "id": "e124",
            "from_node_id": "resp37",
            "to_node_id": "resp48",
            "label": "reason:fact-detail"
        },
        {
            "id": "e125",
            "from_node_id": "resp43",
            "to_node_id": "resp48",
            "label": "evaluate:support"
        },
        {
            "id": "e126",
            "from_node_id": "resp44",
            "to_node_id": "resp48",
            "label": "evaluate:support"
        },
        {
            "id": "e127",
            "from_node_id": "resp45",
            "to_node_id": "resp48",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e128",
            "from_node_id": "resp40",
            "to_node_id": "resp49",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e129",
            "from_node_id": "resp47",
            "to_node_id": "resp49",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e130",
            "from_node_id": "resp48",
            "to_node_id": "resp49",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e131",
            "from_node_id": "resp28",
            "to_node_id": "resp50",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e132",
            "from_node_id": "resp40",
            "to_node_id": "resp50",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e133",
            "from_node_id": "resp41",
            "to_node_id": "resp50",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e134",
            "from_node_id": "resp49",
            "to_node_id": "resp51",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e135",
            "from_node_id": "resp50",
            "to_node_id": "resp51",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e136",
            "from_node_id": "resp17",
            "to_node_id": "resp52",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e137",
            "from_node_id": "resp18",
            "to_node_id": "resp52",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e138",
            "from_node_id": "resp23",
            "to_node_id": "resp52",
            "label": "evaluate:support"
        },
        {
            "id": "e139",
            "from_node_id": "resp27",
            "to_node_id": "resp52",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e140",
            "from_node_id": "resp28",
            "to_node_id": "resp52",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e141",
            "from_node_id": "resp42",
            "to_node_id": "resp52",
            "label": "evaluate:support"
        },
        {
            "id": "e142",
            "from_node_id": "resp43",
            "to_node_id": "resp52",
            "label": "evaluate:support"
        },
        {
            "id": "e143",
            "from_node_id": "resp45",
            "to_node_id": "resp52",
            "label": "evaluate:support"
        },
        {
            "id": "e144",
            "from_node_id": "resp50",
            "to_node_id": "resp52",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e145",
            "from_node_id": "resp43",
            "to_node_id": "resp53",
            "label": "evaluate:support"
        },
        {
            "id": "e146",
            "from_node_id": "resp44",
            "to_node_id": "resp53",
            "label": "evaluate:support"
        },
        {
            "id": "e147",
            "from_node_id": "resp45",
            "to_node_id": "resp53",
            "label": "evaluate:support"
        },
        {
            "id": "e148",
            "from_node_id": "resp52",
            "to_node_id": "resp53",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e149",
            "from_node_id": "resp52",
            "to_node_id": "resp54",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e150",
            "from_node_id": "resp53",
            "to_node_id": "resp54",
            "label": "evaluate:refute"
        },
        {
            "id": "e151",
            "from_node_id": "resp53",
            "to_node_id": "resp55",
            "label": "evaluate:support"
        },
        {
            "id": "e152",
            "from_node_id": "resp54",
            "to_node_id": "resp55",
            "label": "reason:fact-detail"
        },
        {
            "id": "e153",
            "from_node_id": "resp53",
            "to_node_id": "resp56",
            "label": "evaluate:support"
        },
        {
            "id": "e154",
            "from_node_id": "resp55",
            "to_node_id": "resp56",
            "label": "reason:fact-detail"
        },
        {
            "id": "e155",
            "from_node_id": "resp56",
            "to_node_id": "resp57",
            "label": "reason:fact-detail"
        },
        {
            "id": "e156",
            "from_node_id": "resp54",
            "to_node_id": "resp58",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e157",
            "from_node_id": "resp55",
            "to_node_id": "resp58",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e158",
            "from_node_id": "resp56",
            "to_node_id": "resp58",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e159",
            "from_node_id": "resp57",
            "to_node_id": "resp58",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e160",
            "from_node_id": "resp54",
            "to_node_id": "resp59",
            "label": "reason:fact-detail"
        },
        {
            "id": "e161",
            "from_node_id": "resp58",
            "to_node_id": "resp59",
            "label": "reason:plan-step"
        },
        {
            "id": "e162",
            "from_node_id": "resp57",
            "to_node_id": "resp60",
            "label": "reason:fact-detail"
        },
        {
            "id": "e163",
            "from_node_id": "resp59",
            "to_node_id": "resp60",
            "label": "reason:fact-detail"
        },
        {
            "id": "e164",
            "from_node_id": "resp56",
            "to_node_id": "resp61",
            "label": "reason:fact-detail"
        },
        {
            "id": "e165",
            "from_node_id": "resp60",
            "to_node_id": "resp61",
            "label": "reason:fact-detail"
        },
        {
            "id": "e166",
            "from_node_id": "resp53",
            "to_node_id": "resp62",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e167",
            "from_node_id": "resp56",
            "to_node_id": "resp62",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e168",
            "from_node_id": "resp60",
            "to_node_id": "resp62",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e169",
            "from_node_id": "resp61",
            "to_node_id": "resp62",
            "label": "reason:premise-conclusion"
        }
    ]
}